DeepMed Research

West China Hospital of Sichuan University (Sichuan International Hospital)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Disitamab Vedotin
Drug: Penpulimab

First Posted Date: 2023-02-13

Last Posted Date: 2023-02-13

Lead Sponsor: West China Hospital

Target Recruit Count: 20

Registration Number: NCT05726175

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Chengdu, Sichuan, China, China

Left Bundle Branch Pacing Versus Right Ventricular Pacing in Patients With Atrioventricular Block

Recruiting

Conditions: AVB - Atrioventricular Block

Interventions: Procedure: left bundle branch pacing (LBBP)
Procedure: Right ventricular pacing (RVP)

First Posted Date: 2023-02-10

Last Posted Date: 2023-02-10

Lead Sponsor: West China Hospital

Target Recruit Count: 1000

Registration Number: NCT05722379

Locations: 🇨🇳
West China Hospital, Sichuan University, Sichuan, Sichuan, China

Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors

Phase 1

Active, not recruiting

Conditions: Malignant Tumors

Interventions: Biological: EBV mRNA vaccine

First Posted Date: 2023-02-06

Last Posted Date: 2025-05-11

Lead Sponsor: West China Hospital

Target Recruit Count: 19

Registration Number: NCT05714748

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

Vaginal Adventitia Reserved and Anatomical Implant Technique of Transvaginal Mesh Procedure for Pelvic Organ Prolapse

Completed

Conditions: Pelvic Organ Prolapse

Interventions: Procedure: TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique

First Posted Date: 2023-02-01

Last Posted Date: 2023-02-01

Lead Sponsor: West China Hospital

Target Recruit Count: 589

Registration Number: NCT05707533

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

Phase 1

Active, not recruiting

Conditions: Malignant Tumor

Interventions: Biological: EBV immunological agent

First Posted Date: 2023-02-01

Last Posted Date: 2025-05-07

Lead Sponsor: West China Hospital

Target Recruit Count: 19

Registration Number: NCT05707910

Locations: 🇨🇳
West China Hospital, Chendu, Sichuan, China

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Almonertinib

First Posted Date: 2022-12-23

Last Posted Date: 2022-12-23

Lead Sponsor: West China Hospital

Target Recruit Count: 55

Registration Number: NCT05662813

Locations: 🇨🇳
West China Hospital，Sichuan University, Chendu, Sichuan, China

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Phase 2

Recruiting

Conditions: Thyroid Cancer

Interventions: Drug: Tislelizumab
Drug: Anlotinib
Radiation: Radiotherapy

First Posted Date: 2022-12-21

Last Posted Date: 2022-12-21

Lead Sponsor: West China Hospital

Target Recruit Count: 20

Registration Number: NCT05659186

Locations: 🇨🇳
Xingchen Peng, Chengdu, Sichuan, China

Application and Optimization of the International Study Group of Pancreatic Surgery (ISGPS) Definition and Grading Criteria for Postoperative Complications of Pancreatic Surgery in Laparoscopic Pancreatic Surgery

Active, not recruiting

Conditions: Laparoscopic Pancreatic Surgery
Postoperative Bleeding
Delayed Gastric Emptying
Pancreatic Fistula

First Posted Date: 2022-12-20

Last Posted Date: 2022-12-20

Lead Sponsor: West China Hospital

Target Recruit Count: 1000

Registration Number: NCT05657327

Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding

Not Applicable

Not yet recruiting

Conditions: Cirrhosis, Liver
Varice Bleed
Portal Hypertension

Interventions: Drug: Carvedilol
Drug: Propranolol

First Posted Date: 2022-12-15

Last Posted Date: 2022-12-15

Lead Sponsor: West China Hospital

Target Recruit Count: 160

Registration Number: NCT05651789

Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

Phase 1

Recruiting

Conditions: Stomach Neoplasm

Interventions: Combination Product: Capeox regimen combined with Sintilimab and Bevacizumab

First Posted Date: 2022-12-07

Last Posted Date: 2023-05-16

Lead Sponsor: West China Hospital

Target Recruit Count: 57

Registration Number: NCT05640609

Locations: 🇨🇳
Liu Ming, Chengdu, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy